A recent network meta‐analysis investigating pharmacological interventions for UDCA‐resistant PBC management concluded that among second‐line therapies, PPAR agonists demonstrated superior efficacy in improving ALP biochemical levels compared to drugs with alternative mechanisms, with elafibranor exhibiting the highest efficacy, followed by saroglitazar [26]. This evidence concerns the gene PPARA and primary biliary cholangitis.